NovaBay Pharmaceuticals, Inc. (novabay.com) is a healthcare company focused on developing and selling innovative solutions to improve well-being. The company's flagship product, Avenova Antimicrobial Lid and Lash Solution, is designed to clean the skin around the eyes, including the eyelids. This product is particularly effective against microorganisms and debris, thanks to its main ingredient, hypochlorous acid (HOCl), which is a natural part of our immune system. Avenova Spray is formulated with a stable and pure form of HOCl and has been approved by the U.S. Food and Drug Administration (FDA) for sale in the United States.

NovaBay primarily serves consumers who suffer from eye conditions such as blepharitis and dry eye disease. The company reaches its customers through online distribution channels and through prescriptions by eye care professionals. In addition to Avenova Spray, NovaBay offers a range of other eye care products under the Avenova brand, including Novawipes, Avenova Lubricant Eye Drops, Avenova Moist Heating Eye Compress, and the i-Chek.

Operating in the eye care market, NovaBay employs a direct-to-consumer business model, leveraging online sales platforms to reach its customers. This model allows the company to maintain a closer relationship with its end-users and gather valuable feedback for continuous product improvement. NovaBay generates revenue through the sale of its eye care products, both directly to consumers and through healthcare professionals who prescribe and dispense their products.

The company is led by Justin M. Hall, Esq., who has been with NovaBay since 2013 and currently serves as the Chief Executive Officer and General Counsel. Under his leadership, NovaBay focuses on expanding its product line and enhancing its market presence.

Keywords: Antimicrobial, Eye Care, Hypochlorous Acid, FDA-approved, Blepharitis, Dry Eye, Online Distribution, Consumer Health, Eye Drops, Medical Devices.